Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Henrik Ekman portrait

Henrik Ekman

Equity Research Analyst

Coverage

Zerion PharmaQlife Holding

Latest content

ShowingAll content types

Ascelia Pharma: Wrap up from interview with Deputy CEO Julie Waras Brogren

Analyst Comment 20.08.2024 klo 09.25 by Claus Thestrup, Henrik Ekman
Ascelia Pharma

BioPorto: Potential for labelling expansion of NGAL test

Analyst Comment 08.08.2024 klo 12.16 by Claus Thestrup, Henrik Ekman
BioPorto

Gubra: Share price moves to all-time high as another partner project enters phase 1

Analyst Comment 02.07.2024 klo 09.06 by Henrik Ekman, Claus Thestrup
Gubra

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account

Curasight: Management remains confident on its strategy as new financing plan is launched

Analyst Comment 27.06.2024 klo 09.38 by Henrik Ekman, Claus Thestrup
Curasight

Ascelia Pharma: Wrap up from interview with Deputy CEO Julia Waras Brogren

Analyst Comment 18.06.2024 klo 11.48 by Claus Thestrup, Henrik Ekman
Ascelia Pharma

HCA Capital: Wrap up from 2024 Life Science seminar

Analyst Comment 06.06.2024 klo 12.32 by Henrik Ekman, Claus Thestrup
Ascelia PharmaGubraBioPortoPharma Equity Group

Bioporto: New EVP and CFO Niels Høy Nielsen

Analyst Comment 30.05.2024 klo 16.07 by Claus Thestrup, Henrik Ekman
BioPorto

Ascelia Pharma: Wrap up from interview Deputy CEO Julie W. Brogren

Analyst Comment 22.05.2024 klo 09.53 by Claus Thestrup, Henrik Ekman
Ascelia Pharma

Pharma Equity Group: Investors appreciate eventful, and mostly positive, 1. quarter 2024

Analyst Comment 17.05.2024 klo 12.21 by Claus Thestrup, Henrik Ekman
Pharma Equity Group

BioPorto share is markedly up as new CEO for US is hired, and management remains confident at event after strong Q1 report

Analyst Comment 08.05.2024 klo 14.45 by Henrik Ekman
BioPorto
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.